Achieve Life Sciences (ACHV) vs Candel Therapeutics (CADL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed Candel Therapeutics (CADL) over the past year, gaining 118.1% versus a gain of 74.4%. Over five years, CADL leads with a -0.1% price change compared with -10.1% for ACHV. Achieve Life Sciences is the larger company by market cap ($741.3 million vs $739.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | CADL |
|---|---|---|
| Share price | $7.19 | $9.66 |
| Market cap | $741.31M | $739.17M |
| 1-day change | -0.69% | -1.63% |
| YTD return | +45.67% | +73.81% |
| 1-year return | +118.07% | +74.42% |
| 5-year return | -10.06% | -0.10% |
| EPS (TTM) | $-1.69 | $-1.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.64 | $14.00 |
| 52-week low | $2.62 | $4.35 |
| Distance from 52-week high | -16.78% | -31.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +96.80% | +125.16% |
| Average volume | 1.44M | 1.21M |
| Shares outstanding | 103.10M | 76.52M |
| Employees | 28 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACHV has outperformed CADL by 43.6 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
ACHV vs CADL FAQ
Which is bigger, Achieve Life Sciences or Candel Therapeutics?
Achieve Life Sciences (ACHV) is larger, with a market capitalization of $741.31M compared with $739.17M for Candel Therapeutics (CADL).
Which stock has performed better over the past year, ACHV or CADL?
ACHV returned +118.07% over the past 12 months, compared with +74.42% for CADL (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Candel Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Achieve Life Sciences and Biotechnology: Biological Products (No Diagnostic Substances) for Candel Therapeutics.